Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
四川科倫博泰生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6990)

APPROVAL FOR REGISTRATION BY THE CSRC IN RELATION TO SUBSCRIPTION OF NEW DOMESTIC SHARES UNDER SPECIFIC MANDATE

References are made to the announcements of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "**Company**") dated May 8, 2024 and May 16, 2024 and the circular of the 2023 annual general meeting of the Company (the "**2023 AGM**") dated May 21, 2024 (the "**Circular**") in relation to, among other things, the connected transaction involving the proposed Subscription of new Domestic Shares under the Subscription Specific Mandate, and the announcement of the Company dated June 20, 2024 in relation to the poll results of the 2023 AGM. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Company is pleased to announce that it has recently received the Approval for Registration in relation to the Issuance of Shares by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Specific Subscriber (Zheng Jian Xu Ke [2024] No. 1621)《關於同意四川科倫博泰生物醫藥股份有限公司向特定對象發行股票註冊的批覆》(證監許可[2024]1621號) (the "**Approval**") dated November 19, 2024 issued by the China Securities Regulatory Commission (the "**CSRC**"), pursuant to which the CSRC has approved the proposed issue of new Domestic Shares to the Subscriber under the Subscription. Details of the Approval are set out below:

I. The application for registration of the issuance of Shares by the Company to the specific subscriber has been approved.

II. The issuance of Shares shall be implemented strictly in accordance with the application documents submitted to the CSRC.

III. The Approval shall be valid for a period of 12 months from the date of approval for registration by the CSRC.

IV. From the date of approval for registration by the CSRC to the completion of the issuance, if any significant matters occur to the Company, the Company shall report such matters to the CSRC in a timely manner and handle such matters in accordance with relevant regulations.

The Board will proceed with the Subscription in accordance with the requirements of the Approval and relevant laws and regulations and the Subscription Specific Mandate as approved at the 2023 AGM, and will issue further announcement(s) in compliance with the requirements of the Listing Rules and/or relevant laws and regulations as and when appropriate.

By order of the Board
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
LIU Gexin
Chairman of the Board and Non-executive Director

Hong Kong, November 22, 2024

As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou as executive Director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive Directors.